中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 2
Feb.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(2): 233-238

Research advances in combined artificial liver

DOI: 10.12449/JCH240203

  • Department of Infectious Diseases，Guizhou Provincial People’s Hospital，Guizhou 550000，China

Research funding:

Guizhou Science and Technology Foundation (ZK［2021］Key 013)

More Information
  • Corresponding author: LUO Xinhua， luoxinhua1972@126.com （ORCID： 0000-0001-8285-3063）
  • Received Date: 2023-10-30
  • Accepted Date: 2023-11-29
  • Published Date: 2024-02-19
    Abstract
  • At present， in vitro artificial liver support system has achieved a good therapeutic effect in the diseases such as liver failure due to various causes， non-function state before and after liver transplantation， and severe cholestasis. Non-bioartificial liver （NBAL） is widely used in clinical practice through various combinations of modes， mainly the plasma exchange mode for improving coagulation factors and albumin combined with other modes for enhancing the elimination of toxic substances in the body. Bioartificial liver （BAL）， based on the design concept of the synthesis and transformation of hepatocytes， has achieved rapid development in recent years. Patients with liver failure can almost obtain the normal physiological function of human liver after NBAL detoxification and BAL synthesis and transformation of active substances in the body. NBAL mode combined with BAL with a stable therapeutic effect according to the conditions of the patient is the direction of in vitro support treatment for patients with severe liver disease in the future.

     

    • FullText(HTML)
  • loading
    • References(46)
  • [1]
    SALIBA F, BAÑARES R, LARSEN FS, et al. Artificial liver support in patients with liver failure: A modified DELPHI consensus of international experts[J]. Intensive Care Med, 2022, 48( 10): 1352- 1367. DOI: 10.1007/s00134-022-06802-1.
    [2]
    Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification(2022 edition)[J]. J Clin Hepatol, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.

    中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 4): 767- 775. DOI: 10.3969/j.issn.1001-5256.2022.04.007.
    [3]
    LI XT, YAO Y, ZHENG RJ, et al. Analysis of curative effect and short-term survival rate of plasma exchange and double plasma molecular adsorption combined with half-volume plasma exchange in the treatment of liver failure[J]. Chin J Hepatol, 2023, 31( 7): 736- 741. DOI: 10.3760/cma.j.cn501113-20230228-00083.

    李新婷, 姚瑶, 郑嵘炅, 等. 血浆置换与双重血浆分子吸附联合半量血浆置换对肝衰竭治疗的疗效及短期生存率分析[J]. 中华肝脏病杂志, 2023, 31( 7): 736- 741. DOI: 10.3760/cma.j.cn501113-20230228-00083.
    [4]
    WU C, PENG W, CHENG D, et al. Efficacy and economic evaluation of nonbiological artificial liver therapy in acute-on-chronic hepatitis B liver failure[J]. J Clin Transl Hepatol, 2023, 11( 2): 433- 440. DOI: 10.14218/JCTH.2022.00106.
    [5]
    GAO Q, CHEN J, ZHAO C, et al. Combination of plasma exchange and adsorption versus plasma exchange in pediatric acute liver failure: A multicenter cohort study[J]. J Pediatr Gastroenterol Nutr, 2023, 76( 6): 710- 715. DOI: 10.1097/MPG.0000000000003759.
    [6]
    YANG CF, ZHANG Z, ZHANG XY, et al. Artificial liver support system in pediatric acute liver failure due to mushroom poisoning: Case series[J]. Ann Hepatol, 2021, 23: 100290. DOI: 10.1016/j.aohep.2020.100290.
    [7]
    TAN YW, SUN L, ZHANG K, et al. Therapeutic plasma exchange and a double plasma molecular absorption system in the treatment of thyroid storm with severe liver injury: A case report[J]. World J Clin Cases, 2019, 7( 10): 1184- 1190. DOI: 10.12998/wjcc.v7.i10.1184.
    [8]
    ZHOU J, WANG XX, LIAN JS, et al. Comparison of efficacy and safety between artificial liver plasma dia-filtration(PDF) and plasma exchange with continuous veno-venous hemofiltration(FPE+CVVH) for mid and late stage liver failure[J]. Chin J Clin Infect Dis, 2018, 11( 5): 369- 373. DOI: 10.3760/cma.j.issn.1674-2397.2018.05.008.

    周健, 王笑笑, 连江山, 等. 人工肝血浆透析滤过与选择性血浆置换联合连续性血液滤过治疗中晚期肝衰竭疗效及安全性比较[J]. 中华临床感染病杂志, 2018, 11( 5): 369- 373. DOI: 10.3760/cma.j.issn.1674-2397.2018.05.008.
    [9]
    NAKAE H, IGARASHI T, TAJIMI K, et al. A case report of hepatorenal syndrome treated with plasma diafiltration(selective plasma filtration with dialysis)[J]. Ther Apher Dial, 2007, 11( 5): 391- 395. DOI: 10.1111/j.1744-9987.2007.00505.x.
    [10]
    DUAN W, XIAO ZH, YANG LG, et al. Kikuchi’s disease with hemophagocytic lymphohistiocytosis: A case report and literature review[J]. Medicine, 2020, 99( 51): e23500. DOI: 10.1097/MD.0000000000023500.
    [11]
    OIWA H, YOSHIDA S, OKADA H, et al. Atypical drug-induced hypersensitivity syndrome with multiple organ failure rescued by combined acute blood purification therapy: A case report[J]. Int J Emerg Med, 2023, 16( 1): 33. DOI: 10.1186/s12245-023-00511-2.
    [12]
    EGUCHI Y. Plasma dia-filtration for severe sepsis[J]. Contrib Nephrol, 2010, 166: 142- 149. DOI: 10.1159/000314864.
    [13]
    KOMURA T, TANIGUCHI T, SAKAI Y, et al. Efficacy of continuous plasma diafiltration therapy in critical patients with acute liver failure[J]. J Gastroenterol Hepatol, 2014, 29( 4): 782- 786. DOI: 10.1111/jgh.12440.
    [14]
    KINJO N, HAMADA K, HIRAYAMA C, et al. Role of plasma exchange, leukocytapheresis, and plasma diafiltration in management of refractory macrophage activation syndrome[J]. J Clin Apher, 2018, 33( 1): 117- 120. DOI: 10.1002/jca.21570.
    [15]
    INOUE N, SATO A, IKAWA Y, et al. Successful treatment of exertional heat stroke using continuous plasma diafiltration[J]. J Clin Apher, 2016, 31( 5): 490- 492. DOI: 10.1002/jca.21439.
    [16]
    LI K, YANG XL, YANG DK. Effects of three modes of artificial liver therapy on liver function, coagulation function and survival rate in patients with acute liver failure[J]. China J Prac Med, 2020, 47( 16): 55- 58. DOI: 10.3760/cma.j.cn115689-20200507-02155.

    李剀, 杨晓莉, 杨道坤. 三种模式非生物型人工肝对急性肝衰竭患者肝功能、凝血功能及生存率的影响[J]. 中国实用医刊, 2020, 47( 16): 55- 58. DOI: 10.3760/cma.j.cn115689-20200507-02155.
    [17]
    LALEMAN W, WILMER A, EVENEPOEL P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure[J]. Crit Care, 2006, 10( 4): R108. DOI: 10.1186/cc4985.
    [18]
    HASSANEIN TI, TOFTENG F, BROWN RS Jr, et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis[J]. Hepatology, 2007, 46( 6): 1853- 1862. DOI: 10.1002/hep.21930.
    [19]
    MITZNER SR, STANGE J, KLAMMT S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: Results of a prospective, randomized, controlled clinical trial[J]. Liver Transpl, 2000, 6( 3): 277- 286. DOI: 10.1002/lt.500060326.
    [20]
    GERTH HU, POHLEN M, THÖLKING G, et al. Molecular adsorbent recirculating system can reduce short-term mortality among patients with acute-on-chronic liver failure-a retrospective analysis[J]. Crit Care Med, 2017, 45( 10): 1616- 1624. DOI: 10.1097/CCM.0000000000002562.
    [21]
    SALIBA F, CAMUS C, DURAND F, et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: A randomized, controlled trial[J]. Ann Intern Med, 2013, 159( 8): 522- 531. DOI: 10.7326/0003-4819-159-8-201310150-00005.
    [22]
    MACDONALD AJ, SUBRAMANIAN RM, OLSON JC, et al. Use of the molecular adsorbent recirculating system in acute liver failure: Results of a multicenter propensity score-matched study[J]. Crit Care Med, 2022, 50( 2): 286- 295. DOI: 10.1097/CCM.0000000000005194.
    [23]
    BAÑARES R, IBÁÑEZ-SAMANIEGO L, TORNER JM, et al. Meta-analysis of individual patient data of albumin dialysis in acute-on-chronic liver failure: Focus on treatment intensity[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819879565. DOI: 10.1177/1756284819879565.
    [24]
    SCHAEFER B, SCHAEFER F, WITTMER D, et al. Molecular adsorbents recirculating system dialysis in children with cholestatic pruritus[J]. Pediatr Nephrol, 2012, 27( 5): 829- 834. DOI: 10.1007/s00467-011-2058-8.
    [25]
    RIFAI K. Fractionated plasma separation and adsorption: Current practice and future options[J]. Liver Int, 2011, 31( Suppl 3): 13- 15. DOI: 10.1111/j.1478-3231.2011.02595.x.
    [26]
    SENTÜRK E, ESEN F, OZCAN PE, et al. The treatment of acute liver failure with fractionated plasma separation and adsorption system: Experience in 85 applications[J]. J Clin Apher, 2010, 25( 4): 195- 201. DOI: 10.1002/jca.20238.
    [27]
    KRIBBEN A, GERKEN G, HAAG S, et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure[J]. Gastroenterology, 2012, 142( 4): 782- 789. DOI: 10.1053/j.gastro.2011.12.056.
    [28]
    RIFAI K, BODE-BOEGER SM, MARTENS-LOBENHOFFER J, et al. Removal of asymmetric dimethylarginine during artificial liver support using fractionated plasma separation and adsorption[J]. Scand J Gastroenterol, 2010, 45( 9): 1110- 1115. DOI: 10.3109/00365521.2010.485322.
    [29]
    RIFAI K, HAFER C, ROSENAU J, et al. Treatment of severe refractory pruritus with fractionated plasma separation and adsorption(Prometheus)[J]. Scand J Gastroenterol, 2006, 41( 10): 1212- 1217. DOI: 10.1080/00365520600610154.
    [30]
    BERGIS D, FRIEDRICH-RUST M, ZEUZEM S, et al. Treatment of Amanita phalloides intoxication by fractionated plasma separation and adsorption(Prometheus®)[J]. J Gastrointestin Liver Dis, 2012, 21( 2): 171- 176.
    [31]
    VARDAR R, GUNSAR F, ERSOZ G, et al. Efficacy of fractionated plasma separation and adsorption system(Prometheus) for treatment of liver failure due to mushroom poisoning[J]. Hepato-gastroenterology, 2010, 57( 99-100): 573- 577.
    [32]
    LI LJ, YANG Q, HUANG JR, et al. Study of severe hepatitis treated with a hybrid artificial liver support system[J]. Chin J Dial Artif Organs, 2004, 15( 1): 21- 24.

    李兰娟, 杨芊, 黄建荣, 等. 混合型人工肝支持系统治疗慢性重型肝炎疗效研究[J]. 透析与人工器官, 2004, 15( 1): 21- 24.
    [33]
    DEMETRIOU AA, BROWN RS Jr, BUSUTTIL RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure[J]. Ann Surg, 2004, 239( 5): 660-667; discussion 667-670. DOI: 10.1097/01.sla.0000124298.74199.e5.
    [34]
    ZHANG Z, ZHAO YC, CHENG Y, et al. Hybrid bioartificial liver support in cynomolgus monkeys with D-galactosamine-induced acute liver failure[J]. World J Gastroenterol, 2014, 20( 46): 17399- 17406. DOI: 10.3748/wjg.v20.i46.17399.
    [35]
    WANG Y, ZHENG Q, SUN Z, et al. Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes[J]. Cell Stem Cell, 2023, 30( 5): 617- 631. DOI: 10.1016/j.stem.2023.03.013.
    [36]
    SHI XL, GAO Y, YAN Y, et al. Improved survival of porcine acute liver failure by a bioartificial liver device implanted with induced human functional hepatocytes[J]. Cell Res, 2016, 26( 2): 206- 216. DOI: 10.1038/cr.2016.6.
    [37]
    LI WJ, ZHU XJ, YUAN TJ, et al. An extracorporeal bioartificial liver embedded with 3D-layered human liver progenitor-like cells relieves acute liver failure in pigs[J]. Sci Transl Med, 2020, 12( 551): eaba5146. DOI: 10.1126/scitranslmed.aba5146.
    [38]
    KINASIEWICZ A, GAUTIER A, LEWISKA D, et al. Three-dimensional growth of human hepatoma C3A cells within alginate beads for fluidized bioartificial liver[J]. Int J Artif Organs, 2008, 31( 4): 340- 347. DOI: 10.1177/039139880803100411.
    [39]
    LEE JH, LEE DH, LEE S, et al. Functional evaluation of a bioartificial liver support system using immobilized hepatocyte spheroids in a porcine model of acute liver failure[J]. Sci Rep, 2017, 7( 1): 3804. DOI: 10.1038/s41598-017-03424-2.
    [40]
    CHEN HS, JOO DJ, SHAHEEN M, et al. Randomized trial of spheroid reservoir bioartificial liver in porcine model of posthepatectomy liver failure[J]. Hepatology, 2019, 69( 1): 329- 342. DOI: 10.1002/hep.30184.
    [41]
    LI Y, WU Q, WANG Y, et al. Novel spheroid reservoir bioartificial liver improves survival of nonhuman Primates in a toxin-induced model of acute liver failure[J]. Theranostics, 2018, 8( 20): 5562- 5574. DOI: 10.7150/thno.26540.
    [42]
    KUDDUS R, PATZER JF 2nd, LOPEZ R, et al. Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus[J]. Transplantation, 2002, 73( 3): 420- 429. DOI: 10.1097/00007890-200202150-00017.
    [43]
    GERLACH JC. Bioreactors for extracorporeal liver support[J]. Cell Transplant, 2006, 15( Suppl 1): S91- S103. DOI: 10.3727/000000006783982296.
    [44]
    POYCK PP, PLESS G, HOEKSTRA R, et al. In vitro comparison of two bioartificial liver support systems: MELS CellModule and AMC-BAL[J]. Int J Artif Organs, 2007, 30( 3): 183- 191. DOI: 10.1177/039139880703000302.
    [45]
    CALISE F, MANCINI A, AMOROSO P, et al. Functional evaluation of the AMC-BAL to be employed in a multicentric clinical trial for acute liver failure[J]. Transplant Proc, 2001, 33( 1-2): 647- 649. DOI: 10.1016/s0041-1345(00)02183-7.
    [46]
    ADAM AAA, van WENUM M, van der MARK VA, et al. AMC-Bio-Artificial Liver culturing enhances mitochondrial biogenesis in human liver cell lines: The role of oxygen, medium perfusion and 3D configuration[J]. Mitochondrion, 2018, 39: 30- 42. DOI: 10.1016/j.mito.2017.08.011.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (358) PDF downloads(86) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return